
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
<a href="https://news.google.com/rss/articles/CBMi1AJBVV95cUxNOGFQTUJxWktzSFdRaklDX1o2eGQ5V3k3TVpvY2g4aFdTY2xrWTBXV2xiRm04SnB5NEZ4YTZvWEp4UWhNX0hzMHdBRkYyME84ckxnN2VHN2Jlc0pIUTRmUGpwVHBOdHlGVVViWDRmMUdkMTlBQTRSajMyYkhvc05mbTN5T0R6Y2M1czV4bDg0UmlPZ2VlMkxKUG0wam5ZZVhQdDZZVVVCV2tsd0hOc3ZGRk1hQ3NZV1VGZ0gyUkxiaU1yQ1NHZVhNakVRV3R0YWIwckdLODRSQl84RTJrSmJ1blRZcDQ0WHAtWUVpOGZwU3BLdjRUV1EzOHA2RW5aZ2Q3YXB3aHV0ektIM1pEME5WQnBjOV8wZ18zQmU3S2d3SFFrMHY5V2IzYzRqeko3Q0J2T3h5OG8xOXBDejVtSjRGcVdicy1MdkNDLVlaZWpqbTAzS0lU?oc=5" target="_blank">Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>

